Abstract:Abstract Background / Objectives: A novel long-term animal model for human Graves’ disease (GD) was recently established in mice (Endocrinology 2015; 156: 1577-1589) using nine immunizations with recombinant adenovirus (Ad) expressing the extracellular A-subunit of the human thyrotropin receptor (TSHR) over 10 months. The aim of the present study is to detect and measure TSHR-Ab in the animal model of Ad-TSHR immunized mice. Methods: Female BALB/c mice received either 1010 plaque-forming units of adenovirus carrying the A-subunit of the TSHR gene or the green fluorescent protein (GFP) gene (injected into the femoral muscles). In addition, age-matched immunologically naïve mice were studied. Blood was withdrawn out of the left or right tail vein or intracardially (end of the study). The study protocol used three three-weekly immunizations (initiation), followed by a maintenance phase with further regular four-weekly boosts until the ninth immunization. Serum TSHR stimulating (TSAb) and -blocking (TBAb) Ab were measured with reporter bioassays. TSAb was reported as percentage of specimen-to-reference ratio (cut-off SRR% <140). Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine TSH alone (% inhibition <34). Results: A total of twenty-two BALB/c mice were studied (ten, eight, and four Ad-TSHR, control, and Ad-GFP-immunized mice, respectively). All twelve control- and Ad-GFP-immunized mice were negative for both thyrotropin-binding inhibitory immunoglobulins (TBII) as well as for TSAb and TBAb measured with the cell-based bioassays. In contrast, baseline TBII were highly positive in all Ad-TSHR-immunized mice (median 40 IU/L, 25%-75% percentiles 40-40 IU/L, normal cut-off 0.55 IU/L) All these mice also developed hyperthyroidism with elevated free T4 (fT4) levels (median 4.5 ng/dl, 25-75 percentile 4.1-6 ng/dl; normal range 0.9-1.8 ng/dl). All control (0.1, 0.1-0.1 IU/L) and Ad-GFP-immunized (0.2, 0.1-0.3 IU/L) mice were TBII negative and the corresponding fT4 levels were 2.2 ng/dl (2.1-2.4 ng/dl) and 2 ng/dl (1.9-2.1 ng/dl), respectively (p<0.001 for both TBII and fT4 versus Ad-TSHR mice). The serum positivity for TSAb and TBAb in a total of 28 consecutive samples obtained from ten Ad-TSHR mice was 12 (43%) and 21 (75%), respectively. Especially, serum samples of two (20%) Ad-TSHR mice were highly positive in the TSAb bioassay only with a SRR% value of 397 (329-465, p<0.001 vs. control mice). In comparison, sera of four Ad-TSHR mice (40%) were highly positive when measured with the TBAb bioassay only showing a % inhibition value of 69 (63-76). Furthermore, serum samples of four Ad-TSHR mice (40%) demonstrated dual TSAb/TBAb positivity. Conclusions: Functional TSHR-Ab are highly prevalent in Ad-TSHR immunized mice, thus confirming the successful establishment of a novel, long-term animal model for GD.

The Immune Responses in Graves' Disease Mouse Model As Investigated Through Synthetic Linear Peptides

The Significance Of Immune-Related Molecule Expression Profiles In An Animal Model Of Graves' Disease

An improved method for the establishment of a model of Graves' disease in BALB/c mice

Peptidomic profiling of endogenous peptides in the spleens of mouse models of Graves' disease

Establishment of BALB/c mice models for Graves disease

Studies on the development of a mouse model of Graves' disease

An experimental study on the induction of Graves′ hyperthyroidism with Graves′ ophthalmopathy in BALB/c mice by TSHR gene immunization

Induction of Experimental Graves' Disease in Balb/c Mice Immunized with Human Thyrotropin Receptor Ectodomain Amino Terminus Gene

Induction of Murine Neonatal Tolerance Against Graves' Disease Using Recombinant Adenovirus Expressing the TSH Receptor A-subunit.

Determination of Th17 cellular function and IL-10 in the mice of experimental Graves disease model

Impairment of Regulatory Capacity of Cd4(+)Cd25(+) Regulatory T Cells Mediated by Dendritic Cell Polarization and Hyperthyroidism in Graves' Disease

SAT-557 Functional Thyrotropin Receptor Antibodies Confirm a Novel Graves' Disease Animal Model

Immunotherapy with a Biologically Active ICAM-1 Mab and an Sirna Targeting TSHR in a BALB/c Mouse Model of Graves' Disease.

The Influence of Dihydrotestosterone on the Development of Graves' Disease in Female Balb/C Mice

Gene Therapy of Experimental Autoimmune Thyroiditis Mice by in Vivo Administration of Plasmid Dna Coding for Human Interleukin-10

[Murine Model of Graves Disease Induced by Thyroid-Stimulating Hormone Receptor Gene Transfected Via Liposome].

Study on Induction of Immunotolerance Against Graves' Disease in Neonatal Mice

Preparation of animal model for Graves' disease in female mice

Mouse model of Graves' orbitopathy induced by the immunization with TSHR A and IGF-1R α subunit gene

Expression of IFNα-inducible Genes and Modulation of HLA-DR and Thyroid Stimulating Hormone Receptors in Graves’ Disease

[The Influence of Dihydrotestosterone on Cytokine Releases in Male Mice Model with Graves Disease].